Journal: Neuropsychopharmacology

Abbreviation

Neuropsychopharmacol.

Publisher

Nature

Journal Volumes

ISSN

0893-133X
1740-634X

Description

Filters

Reset filters

Search Results

Publications 1 - 10 of 41
  • The Effects of Temporary Inactivation of the Core and the Shell Subregions of the Nucleus Accumbens on Prepulse Inhibition of the Acoustic Startle Reflex and Activity in Rats
    Item type: Journal Article
    Pothuizen, Helen H.J.; Jongen-Rêlo, Ana L.; Feldon, Joram (2005)
    Neuropsychopharmacology
  • Interactive effects between hemizygous 15q13.3 microdeletion and peripubertal stress on adult behavioral functions
    Item type: Journal Article
    Giovanoli, Sandra; Werge, Thomas M.; Mortensen, Preben B.; et al. (2019)
    Neuropsychopharmacology
  • From symptom-based heterogeneity to mechanism-based profiling in youth ADHD: the promise of computational psychiatry
    Item type: Review Article
    Ging-Jehli , Nadja R.; Pine , Daniel S. (2026)
    Neuropsychopharmacology
    Mental health conditions such as attention-deficit/hyperactivity disorder (ADHD) and mood disorders show marked symptom heterogeneity, complicating diagnosis and treatment. Computational psychiatry offers a way forward by using mathematical models, such as sequential sampling models, applied to trial-by-trial behavior in well-defined neurocognitive tasks, to infer latent mechanisms underlying behavior. In ADHD, this approach has revealed consistent alterations in information integration (reduced drift rates) in attention-demanding tasks and also indicates that combinations of different model parameters (increased drift rate and longer nondecision time) distinguish the different neurocomputational mechanisms that underlie symptom dimensions. Early work in ADHD also suggests that drift rate predicts illness trajectories and provides insights into treatment response. Yet current applications remain preliminary, limited by task constraints, assumptions in model specification, and questions of reliability and generalizability of the derived parameters. Integrating mechanistic modeling with naturalistic tasks, physiological measures, and longitudinal designs may help to disentangle context-specific from generalizable processes. Ultimately, shifting from symptom descriptions to mechanistic models of belief and behavioral adaptation in dynamic environments may pave the way for next-generation assessments in ADHD, and help to support interventions that are ecologically valid, developmentally informed, and adaptive to patients’ changing needs across time and context.
  • Oxytocin induces long-lasting adaptations within amygdala circuitry in autism: a treatment-mechanism study with randomized placebo-controlled design
    Item type: Journal Article
    Alaerts, Kaat; Bernaerts, Sylvie; Prinsen, Jellina; et al. (2020)
    Neuropsychopharmacology
  • Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study
    Item type: Journal Article
    Webb, Christian A.; Dillon, Daniel G.; Pechtel, Pia; et al. (2016)
    Neuropsychopharmacology
  • Big behavior: challenges and opportunities in a new era of deep behavior profiling
    Item type: Review Article
    von Ziegler, Lukas; Sturman, Oliver; Bohacek, Johannes (2021)
    Neuropsychopharmacology
    The assessment of rodent behavior forms a cornerstone of preclinical assessment in neuroscience research. Nonetheless, the true and almost limitless potential of behavioral analysis has been inaccessible to scientists until very recently. Now, in the age of machine vision and deep learning, it is possible to extract and quantify almost infinite numbers of behavioral variables, to break behaviors down into subcategories and even into small behavioral units, syllables or motifs. However, the rapidly growing field of behavioral neuroethology is experiencing birthing pains. The community has not yet consolidated its methods, and new algorithms transfer poorly between labs. Benchmarking experiments as well as the large, well-annotated behavior datasets required are missing. Meanwhile, big data problems have started arising and we currently lack platforms for sharing large datasets—akin to sequencing repositories in genomics. Additionally, the average behavioral research lab does not have access to the latest tools to extract and analyze behavior, as their implementation requires advanced computational skills. Even so, the field is brimming with excitement and boundless opportunity. This review aims to highlight the potential of recent developments in the field of behavioral analysis, whilst trying to guide a consensus on practical issues concerning data collection and data sharing.
  • Behavioral and neurochemical vulnerability during adolescence in mice
    Item type: Journal Article
    Adriani, Walter; Granstrem, Oleg; Macrì, Simone; et al. (2004)
    Neuropsychopharmacology
  • Apomorphine-Induced Prepulse Inhibition Disruption is Associated with a Paradoxical Enhancement of Prepulse Stimulus Reactivity
    Item type: Journal Article
    Yee, Benjamin K.; Russig, Holger; Feldon, Joram (2003)
    Neuropsychopharmacology
  • Gamma-hydroxybutyrate to promote slow-wave sleep in major depressive disorder: a randomized crossover trial
    Item type: Journal Article
    Bavato, Francesco; Schnider, Laura K.; Dornbierer, Dario A.; et al. (2025)
    Neuropsychopharmacology
    In major depressive disorder (MDD), main clinical features include insomnia and increased daytime sleepiness. However, specific treatment options to promote sleep in MDD are limited. Gamma-hydroxybutyrate (GHB, administered as sodium oxybate) is a GHB/GABAB receptor agonist used clinically in narcolepsy, where it promotes restorative slow-wave sleep (SWS) while reducing next-day sleepiness. Hence, we performed a randomized, placebo- and active comparator-controlled, double-blind, crossover trial to investigate the sleep-promoting properties of GHB in individuals with MDD. Outpatients aged 20-65 years fulfilling the DSM-5 criteria for MDD were enrolled. A single nocturnal dose of GHB (50 mg/kg) was compared with a single evening dose of the clinical competitor trazodone (1.5 mg/kg) and placebo. Of 29 randomized patients, 23 received at least one intervention and were included in the analysis. Primary outcomes were nocturnal slow wave sleep ([SWS] assessed by polysomnography), next-day vigilance (median response time and number of lapses on the psychomotor vigilance test [PVT]), next-day working memory (median speed and accuracy on an N-back task), and next-day plasma brain-derived neurotrophic factor (BDNF) levels. GHB robustly prolonged SWS compared to both trazodone and placebo. GHB also prolonged total sleep time and enhanced sleep efficiency, while reducing sleep stages N1, N2, and wake-after-sleep-onset. While the median response time on the next-day PVT was unaffected, GHB reduced the number of lapses compared to trazodone and placebo. No effects on next-day working memory performance and BDNF levels were observed. No serious adverse events occurred. Overall, a single nocturnal dose of GHB effectively promotes SWS and shows more favorable effects on next-day vigilance than trazodone and placebo. Future studies should investigate GHB in clinical settings, including repeated administration.
Publications 1 - 10 of 41